Transforming the Funding of Life Sciences Through Collaborative Capital

Royalty Pharma

Transforming the Funding
of Life Sciences Through
Collaborative Capital

Engage With Us

We work directly with innovators across
the life sciences, including research
institutions, inventors, and biopharma
companies.

Engage
Royalty Monetization

ROYALTY MONETIZATION

Our strategy is simple: we acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of our diversified portfolio.

R&D PARTNERSHIPS

We work with drug developers to invest directly in late-stage clinical trials across all therapeutic areas. We prioritize alignment with our partners throughout the pharmaceutical life cycle by sharing in clinical development, regulatory approval and commercialization.

R&D
!!!ALT

M&A

We take a flexible approach to acquisitions and in-licensing transactions. Allowing companies to focus their resources on strategic assets, Royalty Pharma is the ideal partner for biopharma M&A.

Portfolio

The quality and scale of Royalty Pharma’s portfolio of pharmaceutical royalties is unparalleled in the industry. Since 1996, we have meticulously acquired royalty interests in many of the industry’s leading drugs by sales addressing serious unmet medical needs.

Investment Management Team

Pablo L.

Pablo Legorreta

Founder & Chief Executive Officer
Susannah Gray

Susannah Gray

Executive Vice President & Chief Financial Officer
Jim Reddoch

Jim Reddoch

Executive Vice President, Head of Research & Investments
George Lloyd

George Lloyd

Executive Vice President, Investment & General Counsel

OUR HISTORY

Since 1996, Royalty Pharma has expanded the traditional parameters that define a pharmaceutical company. Our disciplined focus, deep fundamental diligence, and collaborative approach to investing, makes us the global leader in the acquisition of pharmaceutical royalty interests.